Operating Income (Loss) of Telomir Pharmaceuticals, Inc. from 31 Mar 2024 to 31 Mar 2025

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Telomir Pharmaceuticals, Inc. quarterly Operating Income (Loss) in USD history and change rate from 31 Mar 2024 to 31 Mar 2025.
  • Telomir Pharmaceuticals, Inc. Operating Income (Loss) for the quarter ending 31 Mar 2025 was $2,187,872, a 14% increase year-over-year.
Source SEC data
View on sec.gov
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Change (%)

Telomir Pharmaceuticals, Inc. Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $2,187,872 +$271,808 +14% 01 Jan 2025 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q1 2024 $1,916,064 01 Jan 2024 31 Mar 2024 10-Q 14 May 2025 2025 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.